セトロレリクス
セトロレリクス 物理性質
- 融点 :
- >259°C (dec.)
- 比重(密度) :
- 1.42±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- Refrigerator
- 溶解性:
- DMSO（微量、加温）、メタノール（微量）
- 外見 :
- 個体
- 酸解離定数(Pka):
- 9.82±0.15(Predicted)
- 色:
- ホワイトからオフホワイト
- InChIKey:
- SBNPWPIBESPSIF-MHWMIDJBSA-N
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
|
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H360 |
生殖能または胎児への悪影響のおそれ |
生殖毒性 |
1A, 1B |
危険 |
|
|
|
| 注意書き |
|
セトロレリクス 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
セトロレリクス 化学特性,用途語,生産方法
効能
性腺刺激ホルモン放出ホルモン受容体拮抗薬
説明
Cetrorelix was launched in Germany for the treatment of
female infertility. It is a decapeptidic analog of luteinizing hormone-releasing
hormone (LH-RH) bearing structural modifications in the crucial positions 1, 2, 3,
6 and 10 : [Ac-D-Nal1, D-4-CI Phe-2, D-Pal3, D-Cit6, D-Alal0]-GnRH. Cetrorelix
is an extremely potent and long acting gonadotrophin releasing hormone
(GnRH) antagonist and thus blocks gonadotrophins and sex steroid secretion
immediately after administration. Moreover, it has a low histamine-releasing
potency. Cetrorelix will be the first LH-RH antagonist approved worldwide. In
several Phase III clinical trials, female patients receiving Cetrorelix had a
successful controlled ovulation thus avoiding a premature LH-surge. Cetrorelix
could be a first-choice in-vitro fertilization (IVF) treatment without the
complications of current controlled ovarian hyperstimulation protocols. Cetrorelix
is currently under clinical investigation for the treatment of diverse sex hormone
dependent disorders such as benign prostate hypertrophy, breast, ovarian or
prostate cancers and diverse gynaecological disorders.
定義
ChEBI: A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-t
rosyl, N5-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH
antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.
セトロレリクス 上流と下流の製品情報
原材料
準備製品
セトロレリクス 生産企業
Global( 239)Suppliers
120287-85-6(セトロレリクス)キーワード:
- 120287-85-6
- Cetrorelix acetate
- CETRORELIX ACID
- CETRIZINEDIHYDROCHLORIDE
- N-Acetyl-3-(2-naphthalenyl)-D-Ala-4-chloro-D-Phe-3-(3-pyridyl)-D-Ala-L-Ser-L-Tyr-N5-(aminocarbonyl)-D-Orn-L-Leu-L-Arg-L-Pro-D-Ala-NH2
- Cetrorelixum
- Cetrorelixum [inn-latin]
- Unii-oon1hfz4ba
- Ac-D-2-Nal-4-chloro-D-Phe-β-(3-pyridyl)-D-Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2 acetate salt
- D-AlaninaMide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aMinocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-
- Ac-D-2-Nal-4-chloro-D-Phe-b-(3-pyridyl)-D-Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2
- AC-(D-ALA[3-(2-NAPHTHYL)])-[D-PHE(4-CL)]-(D-ALA[3-(3-PYRIDYL)])-SER-TYR-(D-CIT)-LEU-ARG-PRO-D-ALA-OH
- Cetrorelix?Acetate impurity
- Cetrorelix acetate USP/EP/BP
- Cetrorelix(Cetrorelix acetate)
- Ac-D2Nal-D4Cpa-D3Pal-DSer-Tyr-DCit-Leu-Arg-Pro-DAla-NH2
- CETRORELIX
- セトロレリックス
- セトロレリクス
- N-アセチル-3-(2-ナフタレニル)-D-Ala-4-クロロ-D-Phe-3-(3-ピリジル)-D-Ala-L-Ser-L-Tyr-N5-(アミノカルボニル)-D-Orn-L-Leu-L-Arg-L-Pro-D-Ala-NH2
- Ac-3-(2-ナフタレニル)-D-Ala-4-クロロ-D-Phe-3-(3-ピリジル)-D-Ala-L-Ser-L-Tyr-N5-(アミノカルボニル)-D-Orn-L-Leu-L-Arg-L-Pro-D-Ala-NH2